Lung Function Testing in Patients With Locally Advanced or Metastatic Solid Tumors

DISEASE CHARACTERISTICS: * Histologically confirmed solid tumor * Locally advanced or metastatic disease * Disease progressed on or after standard therapy OR there is no standard therapy for the malignancy * Standard therapy is defined as first- or second-line therapy that has been shown to provide clinical benefit * Life-long non-smoker * No lung metastasis and/or pleural effusion causing signs or symptoms that impact patient performance status PATIENT CHARACTERISTICS: * ECOG performance status 0-1 * Body mass index ≤ 35 * No concurrent uncontrolled illness including, but not limited to, the following: * Ongoing or active infection * Symptomatic congestive heart failure * Unstable angina pectoris * Ventricular arrhythmia * Psychiatric illness or social situation that would limit compliance with study requirements * No uncontrolled chest or abdominal pain * No oral or facial pain exacerbated by an oral device * No stress incontinence * No COPD, interstitial lung disease, pulmonary embolism, or hemorrhage within the past 6 months * No history of pulmonary fibrosis or pulmonary hypertension * No oxygen requirement at baseline * No asthma * No occupational lung disease, including, but not limited to, asbestos exposure * No polycythemia * No history of connective tissue disease PRIOR CONCURRENT THERAPY: * No prior radiotherapy to the lung * At least 6 months since prior lung surgery * No prior amiodarone hydrochloride * No prior high-dose chemotherapy with autologous or allogeneic hematopoietic stem cell transplantation * No concurrent combination antiretroviral therapy for HIV-positive patients